ITM Isotope Technologies Munich SE: ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors
Kort samengevat
Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a. 177Lu-edotreotide
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij FinanzNachrichten.de.
Lees het volledige bericht ↗